<didl:DIDL xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:didl="urn:mpeg:mpeg21:2002:02-DIDL-NS" xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS" xmlns:dip="urn:mpeg:mpeg21:2002:01-DIP-NS" xmlns:dcterms="http://purl.org/dc/terms/" DIDLDocumentId="https://arxiv.academicsbook.com/id/eprint/10660" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd urn:mpeg:mpeg21:2005:01-DIP-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dip/dip.xsd">
  <didl:Item>
    <didl:Descriptor>
      <didl:Statement mimeType="application/xml">
        <dii:Identifier>https://arxiv.academicsbook.com/id/eprint/10660</dii:Identifier>
      </didl:Statement>
    </didl:Descriptor>
    <didl:Descriptor>
      <didl:Statement mimeType="application/xml">
        <dcterms:modified>2026-05-29T16:23:05Z</dcterms:modified>
      </didl:Statement>
    </didl:Descriptor>
    <didl:Component>
      <didl:Resource mimeType="application/xml" ref="https://arxiv.academicsbook.com/cgi/export/eprint/10660/DIDL/arxiv-eprint-10660.xml"/>
    </didl:Component>
    <didl:Item>
      <didl:Descriptor>
        <didl:Statement mimeType="application/xml">
          <dip:ObjectType>info:eu-repo/semantics/descriptiveMetadata</dip:ObjectType>
        </didl:Statement>
      </didl:Descriptor>
      <didl:Component>
        <didl:Resource mimeType="application/xml">
          <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
        <dc:relation>https://arxiv.academicsbook.com/id/eprint/10660/</dc:relation>
        <dc:title>TREATMENT OF PATISIRAN IN PATIENTS WHO HAS TRANSTHYRETIN CARDIAC AMYLOIDOSIS</dc:title>
        <dc:creator>Abdulhamid, Haydarov</dc:creator>
        <dc:description>Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive cardiomyopathy. Patisiran, an RNA interference therapeutic agent, inhibits the production of hepatic transthyretin</dc:description>
        <dc:publisher>“CENTER FOR ADVANCED STUDIES” LLC</dc:publisher>
        <dc:date>2024-02-27</dc:date>
        <dc:type>Article</dc:type>
        <dc:type>NonPeerReviewed</dc:type>
        <dc:identifier>  Abdulhamid, Haydarov  (2024) TREATMENT OF PATISIRAN IN PATIENTS WHO HAS TRANSTHYRETIN CARDIAC AMYLOIDOSIS.  INTERNATIONAL JOURNAL OF RECENTLY SCIENTIFIC RESEARCHER'S THEORY; Vol. 2 No. 2 (2024): INTERNATIONAL JOURNAL OF RECENTLY SCIENTIFIC RESEARCHER'S THEORY; 283-292.       </dc:identifier>
        <dc:relation>https://uzresearchers.com/index.php/ijrs/article/view/2149</dc:relation></oai_dc:dc>
        </didl:Resource>
      </didl:Component>
    </didl:Item>
    <didl:Item>
      <didl:Descriptor>
        <didl:Statement mimeType="application/xml">
          <dip:ObjectType>info:eu-repo/semantics/humanStartPage</dip:ObjectType>
        </didl:Statement>
      </didl:Descriptor>
      <didl:Component>
        <didl:Resource mimeType="application/html" ref="https://arxiv.academicsbook.com/id/eprint/10660/"/>
      </didl:Component>
    </didl:Item>
  </didl:Item>
</didl:DIDL>